Sera Prognostics

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sera Prognostics reports revenue growth and innovation drive amidst challenges

Sera Prognostics demonstrated strong financial performance with revenue growth and reduced net loss in Q4 2022.
The company's focus on innovation, new data, and upcoming studies positions it well for future growth and market success.
Challenges in revenue expectations and payer dynamics require strategic navigation, but opportunities from studies and technology advancements are promising.

Sera Prognostics reports robust Q1 performance amidst revenue challenges

Sera Prognostics demonstrated strong performance in Q1 2023 with notable revenue growth and positive trial outcomes, showcasing its research capabilities and commitment to innovation.
While facing challenges in revenue projections and financial losses, the company's strategic focus on cost efficiency and strong cash reserves provide a foundation for future growth.
Opportunities lie in upcoming study analyses, continued research efforts, and potential partnerships, positioning Sera Prognostics for sustainable development and market expansion.

Sera Prognostics reports stable Q2 revenue, eyes growth opportunities

Sera Prognostics demonstrated stable financial performance in Q2 2023, with a focus on revenue growth and cost management.
The company's PreTRM test showed promising results in reducing neonatal length of stay, enhancing its market position.
While facing challenges in commercialization and global scaling, Sera has opportunities to expand revenue streams and strengthen partnerships.

SERA reports Q3 revenue growth, focuses on expense management

SERA's financials show revenue growth potential with a focus on expense management
Balancing product development and study outcomes crucial for future success
Strategic steps taken to ensure operational sustainability and revenue growth

Sera Prognostics reports positive study outcomes amidst financial challenges

Sera Prognostics demonstrated positive study outcomes with potential for improved neonatal health, despite a net loss in Q4 2023.
Strategic focus on managing expenses, leveraging study results, and achieving key milestones for future revenue growth.
Opportunities lie in lower cash expenses for 2024, revenue growth initiatives, and the launch of a blood sample self-collection device.
Challenges include balancing financial performance, cash management, and addressing analyst inquiries.

Sera Prognostics reports improved Q1 financials and eyes global expansion

Sera Prognostics made strides in financial performance and operational efficiency in Q1 2024.
The company's focus on expanding test adoption and improving margins shows promise for growth.
Despite challenges like regulatory impacts, Sera Prognostics is poised for strategic investments and market expansion.

Sera Prognostics reports Q2 revenue decline, focuses on growth strategies

Sera Prognostics navigated challenges with decreased revenue and a net loss in Q2 2024, emphasizing cost management and efficiency.
The company's strengths lie in strategic progress, enhanced market visibility, and new market opportunities with the PreTRM Test approval.
Opportunities exist in leveraging study results for product adoption, expanding market reach through awareness initiatives, and utilizing financial flexibility for growth.

Sera Prognostics focuses on combating premature births, strengthens revenue growth

Sera Prognostics is actively working to combat premature birth risks in the U.S.
Despite financial challenges, the company maintains a solid cash position for growth
Strategic initiatives aim to increase revenue and awareness for sustainable progress

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes.

Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates

SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025 and manuscript submission to a quality peer-reviewed journal.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024

SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C.

Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript

SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference:  UBS Genomic Medicine Summit, August 13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond, on August 14 at 8:00 a.m.

Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay Previously, Sera reported that both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant.

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

SALT LAKE CITY , July 1, 2024 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30 th, 2024, ranking them by total market capitalization.

SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION

Ardelyx

Materialise NV

Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10.

3 Stocks Under $10 With the Potential to Make You a Millionaire

SALT LAKE CITY , May 28, 2024 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another step forward for Sera during a year in which we expect to achieve several milestones in advancing our role as 'The pregnancy company' to improve maternal and neonatal healthcare outcomes," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sera Prognostics Conference Call to Review First Quarter Fiscal Year 2024 Results. At this time, all participants are in a listen-only mode.

Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript

SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024. Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication.

SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

SALT LAKE CITY , April 29, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know

Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The PreTRM test analyzes specific proteins and gestational age to provide accurate risk assessment for preterm birth. Sera Prognostics specializes in women's health through its flagship product, PreTRM, with an 88% sensitivity for predicting preterm births.

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

SALT LAKE CITY , March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights: Announced that the Data Safety Monitoring Board (DSMB) overseeing Sera's pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis.

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , March 4, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

News for Sera Prognostics Stock (SERA)